Spots Global Cancer Trial Database for Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
Official Title: Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma
Study ID: NCT00062491
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
For Information call 210-614-1701 for a site near you, Tampa, Florida, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
